Contact Us
Drug Search Results
More Filters [+]

Dalantercept

Alternative Names: dalantercept, ace-041, ace041, ace 041
Latest Update: 2022-10-06
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: TGFR Inhibitor

Novel Mechanism: No

Modality: Fusion Protein

Route of Administration: Oral,Subcutaneous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Merck
Company Location: KENILWORTH NJ 07033
Company CEO: Robert M. Davis
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Dalantercept

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Squamous Cell Carcinoma|Mucinous Cystadenocarcinoma|Serous Cystadenocarcinoma|Mucinous Adenocarcinoma|Transitional Cell Carcinoma|Clear Cell Adenocarcinoma|Endometrial Cancer|Renal Cell Carcinoma|Ovarian Cancer|Head and Neck Cancer|Hepatocellular Carcinoma

Phase 1: Multiple Myeloma

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
A041-05

P2

Completed

Hepatocellular Carcinoma

2017-07-05

A041-04

P2

Terminated

Renal Cell Carcinoma

2017-06-01

GOG-0229N

P2

Completed

Serous Cystadenocarcinoma|Endometrial Cancer|Clear Cell Adenocarcinoma|Mucinous Cystadenocarcinoma|Transitional Cell Carcinoma|Squamous Cell Carcinoma|Mucinous Adenocarcinoma

2016-01-01

GOG-0170R

P2

Completed

Ovarian Cancer

2015-10-31

Recent News Events

Date

Type

Title

04/01/2022

PubMed

 Clinicopathological features and resistance mechanisms in HIP1-ALK-rearranged lung cancer: A multicenter study.

01/01/2022

PubMed

 Targeting the Transforming Growth Factor-beta Signaling Pathway in the Treatment of Gynecologic Cancer.

12/07/2021

PubMed

 Strengthening the FDA's Enforcement of ClinicalTrials.gov Reporting Requirements.

04/28/2021

News Article

 FDA Takes Action For Failure to Submit Required Clinical Trial Results Information to ClinicalTrials.Gov

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions